Paper37586453
Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials.
Liao Y and 1 other. Environ Res, 2023. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials. Papers, record 37586453. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37586453
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Nanoparticles | Major topic |
| Cardiovascular Diseases | Major topic |
| Heart Injuries | Major topic |
| Humans | |
| Polyphenols | |
| Antioxidants | |
| Anti-Inflammatory Agents |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42794525 | Cardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794525 | PubMed |
| 41937498 | Gene Expression Alterations Associated With Resveratrol-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Osteosarcoma Cancer Cells. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/41937498 | PubMed |
| 41697297 | Potent anticancer activity of phenolic-enriched extracts from endemic plants supported by in vitro pharmacological analyses and in silico molecular docking. | Naturwissenschaften | 2026 | https://conductscience.org/library/papers/41697297 | PubMed |
| 40439873 | Radiation-Induced Cardiac Remodeling: Mechanisms and Therapeutic Approaches. | Cardiovasc Toxicol | 2025 | https://conductscience.org/library/papers/40439873 | PubMed |
| 40009315 | Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies. | Cardiovasc Drugs Ther | 2026 | https://conductscience.org/library/papers/40009315 | PubMed |
| 39397196 | Potential Player of Platelet in the Pathogenesis of Cardiotoxicity: Molecular Insight and Future Perspective. | Cardiovasc Toxicol | 2024 | https://conductscience.org/library/papers/39397196 | PubMed |
| 38984581 | Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review. | Recent Pat Anticancer Drug Discov | 2025 | https://conductscience.org/library/papers/38984581 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37586453
GET https://conductscience.org/api/papers/v1/37586453/authors